AKT1 and cholangiocarcinoma: A number of other studies showed similar positive rates of expression of p-MAPK/p-ERK1/2 or p-AKT in cholangiocarcinoma [7], intra-hepatic cholangiocarcinoma [8], and cholangiocarcinoma [13], but the association with clinical and pathological features remain inconclusive.